Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy?

被引：0
|
作者：
Miskovska, Vera [1 ,2 ]
Levy, Antonin [1 ]
Massard, Christophe C. [1 ]
Gross-Goupil, Marine [1 ]
Bossi, Alberto [1 ]
Fizazi, Karim [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med, Villejuif, France
[2] St Elisabeth Canc Inst, Bratislava, Slovakia
来源：
ONKOLOGIE | 2010年 / 33卷 / 03期
关键词：
mediastinal non-seminomatous germ cell tumor; primary; Taxane; Relapse; CISPLATIN-BASED CHEMOTHERAPY; HIGH-DOSE CHEMOTHERAPY;
D O I：
10.1159/000277824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Primary mediastinal non-seminomatous germ cell tumors (NSCGTs) have a poor prognosis in the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. There is no clear standard of treatment at relapse. Between 1995 and 2005, 13 patients experienced progression or relapse, and 1 patient was cured with a taxane-based chemotherapy plus surgical resection at our institution.
引用
收藏
页码：119 / 120
页数：2
相关论文
共 38 条
  • [1] CAN A CURE BE ACHIEVED WITH TAXANE-BASED CHEMOTHERAPY IN PATIENTS WITH PRIMARY MEDIASTINAL NON-SEMINOMATOUS GERM CELL TUMORS (NGCT) AND PROGRESSION OR RELAPSE DESPITE FIRST-LINE CHEMOTHERAPY?
    Miskovska, V.
    Levy, A.
    Sauvin, L. Albiges
    Massard, C.
    Gross-Goupil, M.
    Bossi, A.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 204 - 205
  • [2] First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs)
    Pliarchopoulou, K.
    Pectasides, D.
    CANCER TREATMENT REVIEWS, 2009, 35 (07) : 563 - 569
  • [3] First-line high-dose chemotherapy for 'poor risk' metastatic non-seminomatous testicular germ cell tumors
    Bokemeyer, C
    Harstrick, A
    Beyer, J
    Metzner, B
    Rüther, U
    Hartmann, JT
    Holstein, K
    Derigs, HG
    de Wit, R
    Casper, J
    Schöffski, P
    Kührer, I
    Illiger, HJ
    Kempf, B
    Reichle, A
    Föller, A
    Hossfeld, DK
    Fischer, JT
    Berdel, W
    Gerhartz, H
    Kirchner, H
    Pflüger, K
    Ostermann, H
    Kanz, L
    Schmoll, HJ
    ONKOLOGIE, 1998, 21 : 23 - 25
  • [4] Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience
    De Giorgi, U
    Demirer, T
    Wandt, H
    Taverna, C
    Siegert, W
    Bornhauser, M
    Kozak, T
    Papiani, G
    Ballardini, M
    Rosti, G
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 146 - 151
  • [5] Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers
    De Latour, Bertrand
    Fadel, Elie
    Mercier, Olaf
    Mussot, Sacha
    Fabre, Dominique
    Fizazi, Karim
    Dartevelle, Philippe
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2012, 42 (01) : 66 - 71
  • [6] High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity
    Decatris, MP
    Wilkinson, PM
    Welch, RS
    Metzner, M
    Morgenstern, GR
    Dougall, M
    ANNALS OF ONCOLOGY, 2000, 11 (04) : 427 - 434
  • [7] Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
    Ebrahimi, H.
    Shodiya, M.
    Maldonado, E.
    Othman, T.
    Barragan-Carrillo, R.
    Li, X.
    Rock, A.
    Tripathi, A.
    Pal, S. K.
    Dorff, T. B.
    Zhumkhawala, A.
    Hoeg, R. Tetens
    Oliai, C.
    Olin, R.
    Mei, M.
    Chehrazi-Raffle, A.
    ANNALS OF ONCOLOGY, 2024, 35
  • [8] Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors
    Altan, Mesut
    Haberal, Hakan Bahadir
    Asci, Ahmet
    Gudeloglu, Ahmet
    Dogrul, Ahmet Bulent
    Yazici, Mustafa Sertac
    Akdogan, Bulent
    Ozen, Haluk
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 186 - 191
  • [9] Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors
    Mesut Altan
    Hakan Bahadır Haberal
    Ahmet Aşçı
    Ahmet Güdeloğlu
    Ahmet Bülent Doğrul
    Mustafa Sertaç Yazıcı
    Bülent Akdoğan
    Haluk Özen
    International Journal of Clinical Oncology, 2021, 26 : 186 - 191
  • [10] First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
    Smith, I. E.
    Pierga, J. -Y.
    Biganzoli, L.
    Cortes-Funes, H.
    Thomssen, C.
    Pivot, X.
    Fabi, A.
    Xu, B.
    Stroyakovskiy, D.
    Franke, F. A.
    Kaufman, B.
    Mainwaring, P.
    Pienkowski, T.
    De Valk, B.
    Kwong, A.
    Gonzalez-Trujillo, J. L.
    Koza, I.
    Petrakova, K.
    Pereira, D.
    Pritchard, K. I.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 595 - 602
1234